Market capitalization | $1.28m |
Enterprise Value | $-4.62m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.46 |
EV/Sales (TTM) EV/Sales | -231.00 |
P/S ratio (TTM) P/S ratio | 64.00 |
P/B ratio (TTM) P/B ratio | 0.24 |
Sales growth (TTM) Sales growth | -99.50% |
Turnover (TTM) Turnover | $20.00k |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Histogen Inc:
1 Analyst has issued a forecast Histogen Inc:
Dec '22 |
+/-
%
|
||
Net profit | -11 -11 |
29%
29%
|
|
Depreciation and amortization | 0.14 0.14 |
-
|
|
Share compensation | 0.50 0.50 |
-
|
|
Operating cash flow | -9.68 -9.68 |
-
|
|
Investments | 0.22 0.22 |
-
|
|
Dividend paid | 0.49 0.49 |
-
|
|
Free cash flow | -9.90 -9.90 |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Histogen, Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. The company engages in research, development, and manufacturing of products derived from its technology. It offers an insoluble human extracellular matrix (hECM); and a soluble complex of proteins. The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. It has joint venture with PUR Biologics, Adaptive Biologix, and Histogen Aesthetics to develop additional products. Histogen, Inc. was founded in 2007 and is based in San Diego, California.
Head office | United States |
CEO | Susan Knudson |
Employees | 7 |
Founded | 2005 |
Website | www.histogen.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.